Compare Alexandria Real Estate Equities Inc (ARE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Sana Biotechnology Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.28 (market cap $8.28B), while Sana Biotechnology Inc trades at $3.85 (market cap $1.13B). The key difference: Alexandria Real Estate Equities Inc is far larger — about 7.3× Sana Biotechnology Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ARE | SANA | |
|---|---|---|
Market Cap | $8.28B | $1.13B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $5.92 |
52-Week Low | $40.41 | $2.68 |
Enterprise Value | $20.98B | $1.05B |
Dividend Yield | 5.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.01, down 0.7% on the day, with a bearish technical signal and mixed fundamentals. The stock shows negative profitability with a net income margin of -37.12% and ROE of -6.29% for 2025, though it maintains a strong gross margin of 67.28%. Recent Q2 2026 earnings missed EPS expectations but beat on FFO, with leasing momentum improving. The current price is near the analyst low target of $48.00, with support at $47 and resistance at $49.
Outlook remains cautious due to persistent net losses and high debt, but a 36% analyst buy rating and recent institutional acquisitions suggest potential recovery if leasing trends and FFO guidance hold. Key risks include occupancy pressures, legal scrutiny, and macroeconomic sensitivity. The stock presents a speculative opportunity for value investors betting on a real estate turnaround.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
